A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 58
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : OIPN
Long Form : oxaliplatin-induced peripheral neuropathy
No. Year Title Co-occurring Abbreviation
2023 The neuroprotective effect of pterostilbene on oxaliplatin-induced peripheral neuropathy via its anti-inflammatory, anti-oxidative and anti-apoptotic effects: Comparative study with celecoxib. MDA, TAC
2022 A New Manganese Superoxide Dismutase Mimetic Improves Oxaliplatin-Induced Neuropathy and Global Tolerance in Mice. ROS, SOD
2022 Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. HMGB1
2022 Diosgenin relieves oxaliplatin-induced pain by affecting TLR4/NF-κB inflammatory signaling and the gut microbiota. ---
2022 Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial. CTCAE, NCS
2022 Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients. ADI, AI, BJOEI, CKSI, EEI, HCSI, KAI, KLEI, LI, NMA, RCTs, SFI, SIFZI, SMI, TCMIs, XAPI
2022 NET-Triggered NLRP3 Activation and IL18 Release Drive Oxaliplatin-Induced Peripheral Neuropathy. EPA, NET, NLRP3
2022 New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy. CTCAE, PTT, QST
2022 Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database. FAERS, PPI
10  2022 Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy. ---
11  2022 Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. BMI, CTCAE
12  2022 Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis. BMI, CI, OR
13  2022 Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. GRADE
14  2022 Protective Mechanism of Electroacupuncture on Peripheral Neurotoxicity Induced by Oxaliplatin in Rats. DRG, EA, HO-1, Nrf2, TRP
15  2022 Syringaresinol Alleviates Oxaliplatin-Induced Neuropathic Pain Symptoms by Inhibiting the Inflammatory Responses of Spinal Microglia. iNOS, p-ERK, p-NF-kappaB
16  2022 Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. ---
17  2022 Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months. ---
18  2022 The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice. CRC, DEGs, HDAC, HDACi
19  2022 [Preparation of microemulsion gel loading enriched ingredients of Epimedii Folium and its pharmacodynamics evaluation]. CIPN
20  2021 Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial. PA, QoL
21  2021 Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial. GI, PN, QoL
22  2021 Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial. DFS, MCIPN, OS, PFS, VAS
23  2021 PEA-OXA Mitigates Oxaliplatin-Induced Painful Neuropathy through NF-kappaB/Nrf-2 Axis. DRG, PEA-OXA, PEAum
24  2021 Platinum accumulation in oxaliplatin-induced peripheral neuropathy. CTR1, MATE1
25  2021 Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. DSD, HGWD, YWF
26  2021 Probing the peripheral immune response in mouse models of oxaliplatin-induced peripheral neuropathy highlights their limited translatability. CIPN
27  2021 Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy. CRC, CTSS, IL-10, IRF1
28  2020 A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study. ---
29  2020 A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy. NCI-CTCAE
30  2020 Based on Systematic Pharmacology: Molecular Mechanism of Siwei Jianbu Decoction in Preventing Oxaliplatin-Induced Peripheral Neuropathy. CIPN, IENF
31  2020 Formononetin ameliorates oxaliplatin-induced peripheral neuropathy via the KEAP1-NRF2-GSTP1 axis. FN, Nrf2
32  2020 Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. ---
33  2020 Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin. GGT, Hgb
34  2020 Qualitative Evaluation of the Influence of Acute Oxaliplatin-Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life. QoL
35  2020 Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. NCI-CTC, OCT, sGFAP, sNfL
36  2020 Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity: A protocol for a randomized, controlled, double-blind, multicenter trial. TCM
37  2020 Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2). mCRC
38  2020 Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study. CINQ, PQAS
39  2019 Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study. ADL
40  2019 Differential protein expression profiling by iTRAQ-2D-LC-MS/MS of rats treated with oxaliplatin. ---
41  2019 Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. ---
42  2019 Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. CRC, DFS
43  2018 A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy. NCS
44  2018 Electrochemical Skin Conductance as a Marker of Painful Oxaliplatin-Induced Peripheral Neuropathy. ESC
45  2018 Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. NF-E2
46  2018 Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy. AMPK, CIPN, DRG, RA
47  2017 Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy. DRG
48  2017 Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. DRG
49  2017 Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. TNSc
50  2016 An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi. CPT, GJG
51  2016 Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study. CINQ, LA, OSNS, PQAS
52  2016 Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. CRC, QoL
53  2015 Calcium-related neurotoxicity of oxaliplatin: understanding the mechanisms to drive therapy. ---
54  2015 Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial. HRQoL, PRD
55  2015 Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study. ICC, OANQ
56  2014 A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. NCI-CTC
57  2014 Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. CR, CRC
58  2011 Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. VAS